Investor Relations (3)

Hemostemix Announces Advancements in its Automation of Production

Read More

Hemostemix Contracts ProConsul to Ramp up Engagement with New Investors

Read More

Hemostemix Closes Private Placement of USD $336,500 at $0.295 per Share

Read More

Hemostemix’s Private Placement

Read More

Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences

Read More

Hemostemix Announces Trademark Granted by Switzerland and Interest Payment

Read More

Investor Relations

Hemostemix Settlement via Depository Trust Company Plus OTCQB Update

Read More

Hemostemix Announces NCP-01 Study to Address a $10 Billion Pain Market ​

Read More

Hemostemix Presents at TERMIS 2025, Freiburg, Germany

Read More

Hemostemix Announces Exploring Clinical Trial Financing Alternatives

Read More